The committee will vote on the application in February, Acadia said. The company intends to request a re-examination of the opinion upon the formal vote. Rett syndrome is a rare n ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal ...

Acadia Pharmaceuticals (NasdaqGS:ACAD) received a negative trend vote from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Rett syndrome treatment, trofinetide.

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

The biopharmaceutical company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) delivered an unfavorable preliminary opinion on its ...

Rett syndrome, a rare and severe neurodevelopmental disorder, affects approximately 1 in 10,000 to 1 in 15,000 live bi ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

Biomed Industries, Inc. to Announce Phase 2/3 Results of NA-921 for the Treatment of Rett Syndrome at the IRSF Rett Syndrome Scientific Conference 2025 The Phase 2/3 results of NA-921 shows strong ...

New discoveries about the severe developmental disorder known as Rett syndrome could open the door to better treatments for the devastating, life-shortening condition. Scientists investigating the ...

--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...

Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...